a clinical stage biopharmaceutical company focused on developing and commercializing innovative neuropsychiatric therapeutics. Our clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, an endogenous neurosteroid produced in the central nervous system that modulates the brain neurotransmitter gamma-aminobutyric acid, or GABA. Our lead indication for ganaxolone is as an adjunctive therapy for the treatment of focal, onset seizures in adults with epilepsy... By targeting the same spectrum of GABAA receptors as endogenous allopregnanolone, ganaxolone delivers its therapeutic benefit through a natural mechanism that we believe offers safety and efficacy advantages compared to other marketed antiepileptic medications.www.marinuspharma.com/#!investors/c242w